Found 5 articles
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
UBIX THERAPEUTICS, SK BIOPHARMACEUTICALS ENTER INTO RESEARCH COLLABORATION AGREEMENT TO DEVELOP NOVEL THERAPEUTICS BASED ON TARGETED PROTEIN DEGRADATION
Ubix Therapeutics, SK Biopharmaceuticals to develop new compounds and medicines through Ubix’s Degraducer® technology for cancer treatment.
South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead program, UBX-303, which utilizes Ubix’s platform technology, Degraducer®.
Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates
Debiopharm today announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells.
NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company announced it has entered into an exclusive license agreement with Ubix Therapeutics, Inc. to develop up to three drug candidates utilizing UBIX’s Degraducer® platform technology which enables target protein degradation.